-
Product Insights
NewBone Marrow Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs. The Bone Marrow Transplant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JAB-3068 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JAB-3068 in Non-Small Cell Lung Cancer Drug Details: JAB-3068 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EQ-102 in Celiac Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EQ-102 in Celiac Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EQ-102 in Celiac DiseaseDrug Details:EQ-102 is under development for the treatment of celiac...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1012 in Influenza A Virus, H3N2 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1012 in Influenza A Virus, H3N2 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1012 in Influenza A Virus, H3N2 Subtype InfectionsDrug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07901801 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Refractory Multiple Myeloma Drug Details: Maplirpacept (TTI-622) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Itolizumab in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Itolizumab in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Itolizumab in Graft Versus Host Disease (GVHD) Drug Details:Itolizumab (T1h,...
-
Company Profile
Equillium Inc – Company Profile
Equillium Inc (Equillium) is a biotechnology business that specialises in immunobiology to develop drugs for the treatment of autoimmune and inflammatory illnesses.The company’s pipeline product includes EQ001 (itolizumab), a first-in-class monoclonal antibody that targets the novel immune checkpoint receptor CD6 that inhibits pathogenic cellular pathways for effector T cell development. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium develops its products for immuno-inflammatory diseases across therapeutic...
Add to Basket -
Product Insights
Net Present Value Model: Itolizumab
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Itolizumab Drug Details Itolizumab (T1h, Alzumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EQ-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EQ-101 Drug Details EQ-101 is under development for the treatment of T-cell leukemias including...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – itolizumab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry itolizumab Drug Details Itolizumab (T1h, Alzumab / Anti-CD6 ) is a humanized recombinant anti-CD6...